M. William Audeh

6.8k total citations · 3 hit papers
35 papers, 5.2k citations indexed

About

M. William Audeh is a scholar working on Oncology, Genetics and Cancer Research. According to data from OpenAlex, M. William Audeh has authored 35 papers receiving a total of 5.2k indexed citations (citations by other indexed papers that have themselves been cited), including 27 papers in Oncology, 17 papers in Genetics and 12 papers in Cancer Research. Recurrent topics in M. William Audeh's work include BRCA gene mutations in cancer (15 papers), PARP inhibition in cancer therapy (15 papers) and Advanced Breast Cancer Therapies (7 papers). M. William Audeh is often cited by papers focused on BRCA gene mutations in cancer (15 papers), PARP inhibition in cancer therapy (15 papers) and Advanced Breast Cancer Therapies (7 papers). M. William Audeh collaborates with scholars based in United States, United Kingdom and Australia. M. William Audeh's co-authors include Michael Friedländer, Andrew Tutt, Jeffrey N. Weitzel, Niklas Loman, Rita K. Schmutzler, Mark Wickens, James Carmichael, Susan M. Domchek, Gillian Mitchell and Richard T. Penson and has published in prestigious journals such as The Lancet, Journal of Clinical Oncology and Cancer.

In The Last Decade

M. William Audeh

35 papers receiving 5.0k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial

2010 1.7k citations M. William Audeh, James Carmichael et al. The Lancet profile →
Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial

2010 1.3k citations Andrew Tutt, Mark E. Robson et al. The Lancet profile →
Olaparib Monotherapy in Patients With Advanced Cancer and a Germline BRCA1/2 Mutation

2014 1.2k citations Bella Kaufman, Ronnie Shapira‐Frommer et al. Journal of Clinical Oncology profile →

Peers

M. William Audeh

ONCOL

MB

GENET

CR

RM

Rita K. Schmutzler Germany

Kirsten M. Timms United States

Darren Hodgson United Kingdom

Elizabeth Lowe United States

Bethan Powell United States

Kerry Fenwick United Kingdom

Rachel Brough United Kingdom

Rita K. Schmutzler Germany

Sarah Runswick United Kingdom

Rebecca Kristeleit United Kingdom

Rita K. Schmutzler Germany

M. William Audeh

2.7k ×0.6

ONCOL

2.5k ×0.9

MB

1.3k ×0.9

GENET

917 ×0.8

CR

488 ×0.5

RM

Citations per year, relative to M. William Audeh M. William Audeh (= 1×) peers Rita K. Schmutzler

Countries citing papers authored by M. William Audeh

Since Specialization

Citations

This map shows the geographic impact of M. William Audeh's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by M. William Audeh with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites M. William Audeh more than expected).

Fields of papers citing papers by M. William Audeh

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by M. William Audeh. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by M. William Audeh. The network helps show where M. William Audeh may publish in the future.

Co-authorship network of co-authors of M. William Audeh

This figure shows the co-authorship network connecting the top 25 collaborators of M. William Audeh. A scholar is included among the top collaborators of M. William Audeh based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with M. William Audeh. M. William Audeh is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

1.

Cobain, Erin F., Lajos Pusztai, Cathy Graham, et al.. (2024). Elucidating the immune active state of HR+HER2- MammaPrint High 2 early breast cancer.. Journal of Clinical Oncology. 42(16_suppl). 506–506. 3 indexed citations

2.

Beitsch, Peter D., James Pellicane, Lajos Pusztai, et al.. (2023). MammaPrint Index as a predictive biomarker for neoadjuvant chemotherapy response and outcome in patients with HR+HER2- breast cancer in NBRST.. Journal of Clinical Oncology. 41(16_suppl). 521–521. 3 indexed citations

3.

Chung, Alice, Marissa K. Srour, Farnaz Dadmanesh, et al.. (2022). Identification of transcriptional changes with MammaPrint and BluePrint in early-stage breast cancer after neoadjuvant chemotherapy.. Journal of Clinical Oncology. 40(16_suppl). 585–585. 1 indexed citations

4.

Cynthia, X., Pat W. Whitworth, Svetislava J. Vukelja, et al.. (2022). FLEX, the 30,000 breast cancer transcriptome project: A platform for early breast cancer research using full-genome arrays paired with clinical data.. Journal of Clinical Oncology. 40(16_suppl). TPS612–TPS612. 1 indexed citations

5.

Delahaye, Leonie, Caroline A. Drukker, Christa Dreezen, et al.. (2017). A breast cancer gene signature for indolent disease. Breast Cancer Research and Treatment. 164(2). 461–466. 21 indexed citations

6.

Matulonis, Ursula A., Richard T. Penson, S. M. Domchek, et al.. (2016). Olaparib monotherapy in patients with advanced relapsed ovarian cancer and a germline BRCA1/2 mutation: a multistudy analysis of response rates and safety. Annals of Oncology. 27(6). 1013–1019. 125 indexed citations

7.

Xie, Yu, William Collins, M. William Audeh, et al.. (2015). Breast Cancer Survivorship and Cardiovascular Disease: Emerging Approaches in Cardio-Oncology. Current Treatment Options in Cardiovascular Medicine. 17(12). 60–60. 15 indexed citations

8.

Domchek, Susan M., Carol Aghajanian, Ronnie Shapira‐Frommer, et al.. (2015). Efficacy and safety of olaparib monotherapy in germline BRCA1 / 2 mutation carriers with advanced ovarian cancer and three or more lines of prior therapy. Gynecologic Oncology. 140(2). 199–203. 218 indexed citations

9.

Domchek, Susan M., Ronnie Shapira‐Frommer, Rita K. Schmutzler, et al.. (2015). Efficacy and safety of olaparib monotherapy in a subgroup of patients with a germline BRCA1/2 mutation and advanced ovarian cancer from a Phase II open-label study.. Journal of Clinical Oncology. 33(15_suppl). 5529–5529. 1 indexed citations

10.

Tryfonidis, Konstantinos, Jan Bogaerts, Robert E. Martell, et al.. (2014). A phase III randomized trial of niraparib versus physician’s choice in previously treated, HER2-negative, germline-BRCA mutated breast cancer patients: Intergroup study EORTC-1307-BCG and BIG5-13.. Journal of Clinical Oncology. 32(15_suppl). TPS659–TPS659. 8 indexed citations

11.

Hyams, David M., Arlene Chan, Raymond Snyder, et al.. (2013). Cediranib in combination with fulvestrant in hormone-sensitive metastatic breast cancer: a randomized Phase II study. Investigational New Drugs. 31(5). 1345–1354. 33 indexed citations

12.

Kaufman, Bella, Ronnie Shapira‐Frommer, Rita K. Schmutzler, et al.. (2013). Olaparib monotherapy in patients with advanced cancer and a germ-line BRCA1/2 mutation: An open-label phase II study.. Journal of Clinical Oncology. 31(15_suppl). 11024–11024. 23 indexed citations

13.

Tutt, Andrew, Mark E. Robson, Judy E. Garber, et al.. (2010). Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial. The Lancet. 376(9737). 235–244. 1286 indexed citations breakdown →

14.

Audeh, M. William, James Carmichael, Richard T. Penson, et al.. (2010). Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial. The Lancet. 376(9737). 245–251. 1742 indexed citations breakdown →

15.

Tutt, Andrew, Mark E. Robson, Judy E. Garber, et al.. (2009). Phase II trial of the oral PARP inhibitor olaparib in BRCA-deficient advanced breast cancer. Journal of Clinical Oncology. 27(15_suppl). CRA501–CRA501. 141 indexed citations

16.

Hyams, David M., Carlos Augusto Fernandes de Oliveira, R. Snyder, et al.. (2009). Cediranib in Combination with Fulvestrant in Hormone-Sensitive Metastatic Breast Cancer: A Phase II Randomized Study.. Cancer Research. 69(24_Supplement). 204–204. 5 indexed citations

17.

Tutt, Andrew, Mark E. Robson, Judy E. Garber, et al.. (2009). Phase II trial of the oral PARP inhibitor olaparib in BRCA-deficient advanced breast cancer. Journal of Clinical Oncology. 27(18_suppl). CRA501–CRA501. 98 indexed citations

18.

Audeh, M. William, Charlotte Jacobs, Thomas E. Davis, & Robert W. Carlson. (1990). A Phase II Trial of Carbetimer for the Treatment of Colorectal Cancer. American Journal of Clinical Oncology. 13(4). 324–326. 1 indexed citations

19.

Strickler, John G., M. William Audeh, Cedith M. Copenhaver, & Roger A. Warnke. (1988). Immunophenotypic differences between plasmacytoma/multiple myeloma and immunoblastic lymphoma. Cancer. 61(9). 1782–1786. 26 indexed citations

20.

Clamon, Gerald H., et al.. (1982). Small Cell Lung Carcinoma in the Elderly. Journal of the American Geriatrics Society. 30(5). 299–302. 26 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact